OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Up 7.6 %

Shares of OPGN opened at $1.84 on Thursday. OpGen has a 12 month low of $1.61 and a 12 month high of $9.90. The stock has a fifty day moving average price of $1.94 and a 200-day moving average price of $3.07.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent SEC filing. 2.68% of the stock is currently owned by institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.